Evidence map›Paper›PMID 41792308›Full record

ArticleScientific reports2026

Characteristics of patients diagnosed for acute myeloid leukemia before and during the 2020 COVID-19 pandemic: the DATAML population-based cohort.

Sébastien Lamy, Raphaël Fenni, Suzanne Tavitian, Léopoldine Lapierre, Thibaut Leguay, Jean Galtier, Audrey Sarry, Anne-Charlotte De-Grande, Emilie Berard, Arnaud Pigneux and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sébastien LamyCenter for Epidemiology and Research on Population Health (CERPOP), UMR 1295 Inserm - University of Toulouse III Paul Sabatier, Toulouse, France. sebastien.lamy@inserm.fr.
Raphaël FenniCenter for Epidemiology and Research on Population Health (CERPOP), UMR 1295 Inserm - University of Toulouse III Paul Sabatier, Toulouse, France.
Suzanne TavitianService d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Léopoldine LapierreService d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Thibaut LeguayService d'Hématologie Clinique et de Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France.
Jean GaltierService d'Hématologie Clinique et de Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France.
Audrey SarryService d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Anne-Charlotte De-GrandeService d'Hématologie Clinique et de Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France.
Emilie BerardCenter for Epidemiology and Research on Population Health (CERPOP), UMR 1295 Inserm - University of Toulouse III Paul Sabatier, Toulouse, France.
Arnaud PigneuxService d'Hématologie Clinique et de Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France.
Christian RécherService d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Pierre-Yves DumasService d'Hématologie Clinique et de Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France.
Sarah BertoliService d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Literature shows heterogeneous impact of recommendations to deal with sars-cov-2 infection on AML management during the 2020 Covid-19 pandemic. Available French data only rely on monocentric observations or simulations. From the DATAML cohort, including all AML patients cared for in the centers of South-West France, we compared the characteristics of patients diagnosed in two periods: 2020 and 2015–2019. We use time series approach to describe the monthly proportion of patients with extreme values on hemoglobin, white blood cells, platelets, and blasts counts, as well as early deaths. We found a slight impact of the first lockdown on hemoglobin and platelets, with statistical significance reached only for platelets distribution gap between the two periods. Similar but less marked patterns were found for WBC and blood blasts. These did not translate in terms of early deaths, which was considered to be likely due to a favorable local conjuncture associating a moderate incidence of sars-cov-2 and the absence of bed closing in oncohematology or ICU dedicated to hematology in any centers providing intensive care for AML patients. Yet, our results might still be seen as an insight of what would have happened in less favorable contexts.

Indexed as

COVID-19Leukemia, Myeloid, AcuteAdultAgedAged, 80 and overCohort StudiesFemaleFranceHumansMaleMiddle AgedPandemicsSARS-CoV-2Acute Myeloid LeukemiaAML characteristics at diagnosisCovid-19Observational cohortTemporal variations

Identifiers

PMID41792308
PMCPMC13079849

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.